Pruritic Diseases and Secondary Changes Flashcards
Urticaria most symptomatic
Early lesion and small superficial wheals
How to treat urticaria?
Antihistamines - decrease pruritus - leads to resolution of wheals
Assessment that should be performed in all patient’s with itch?
Dermatographism (exaggerated wheal development) mark the skin to see if a wheal develops
Factors that contribute to itch in atopic dermatitis
Epidermal hyper-innervation and central sensitization
What is nemolizumab
anti-IL-31 receptor A medication used to decrease itch
Scabies itch starts when
- 3-6 weeks after the initial infection
- within days of subsequent
Immune response during scabies targets
Mites
Eggs
Scybala ( fecal matter)
CTCL and itch
> 60% of patients have itch
frequency intensifies at later stages i.e Sezary Syndrome
What cytokine is associated with itch in CTCL
IL-31
Nemolizumab is an antibody against the IL-31 RA
CTCL itch treatment options (experimental)
Nemolizumab
Mogamulizumab
gabapentin 900-2400 mg/day (split into 3 doses)
Mirtazepine 7.5 -15 mg
Naltrexone 50-150 mg/day
Aprepitant (neurokinin 1 blocker)
Prurigo Nodularis
Dome shaped, firm, hyperpigmented papulonodules +/- central crust/scale/erosion
Prurigo Nodularis Distribution
Symmetrically along the extremities (typically extensor surface)
Butterfly sign with sparing of the upper mid back
Also spares flexural areas, face and groin
Prurigo Nodularis Causes
chronic repetitive scratching/picking due to a pruritic systemic or dermatological or psychogenic diseaese
Prurigo Nodularis Epidemiology
Middle aged adult with dermatologic/psychiatric diseases
occasionally in children with atopic dermatitis
Prurigo Nodularis Pathology
Epidermal hyperplasia
Compact hyperkeratosis
Vertically arranged collagen fibers
increased number of fibroblasts and capillaris
perivascular/ interstitial mixed inflammatory infiltrate
increased dermal nerve fibers
decreased epidermal nerve fibers
Prurigo Nodularis Treatments
Psychogenic- SSRIs/TCA
thalidomide (50-200mg/day)/lenalidomide
Liquid nitrogen
Topical capsaicin
calcipotreine
cyclosporine
doxepin
methotrexate
Products with anti-itch properties
pramoxine (cerave itch relief)
polidocanol (asclera, vanthena)
palmitoylethanolamine
oral antihistamines
- Non sedating- cetirizine (Zyrtec)
fexofenadine (Allegra)
loratadine (claritin)
desloratadine (clarinex)
Lichen simplex chronicus
well defined plaques exhibiting exaggerated skin lines with a leathery appearance
Lichen simplex chronicus locations
posteriolateral neck
occipital scalp
anogenital region
shins, ankles
dorsal aspects of the feet,hands forearms
lichen simplex chronic pathology
compact hyperkeratosis
acanthosis with irregular elongation
vertically oriented collagen fibers in the papillary dermis
hypergranulosis
lichen simplex chronicus epidemiology
more common in older adults
lichen simplex chronicus Treatments
Avoidance of scratching/itching
topical / intralesional steriods or calcineurin inhibitors
menthol and pramoxine
anti-histamines
behavioral therapy
lidocaine patch
capsacin patches
Scalp pruritus
Primary- lacks skin lesions; associated with anxiety, depression
Secondary- folliculitis, seb derm ,psoriasis
Treatment- emoillents, topical steroid, tar or salicylic acid shampoos, low dose doxepin
Pruritus Ani Epidemiology and appearance
Male>> Female- 4:1 ratio
Appear normal to severely irritated